{"meshTags":["Melanoma","Neoplasm Metastasis","Antineoplastic Combined Chemotherapy Protocols","Recombinant Proteins","Antibodies, Monoclonal","Granulocyte-Macrophage Colony-Stimulating Factor","Meta-Analysis as Topic","CTLA-4 Antigen","Humans"],"meshMinor":["Melanoma","Neoplasm Metastasis","Antineoplastic Combined Chemotherapy Protocols","Recombinant Proteins","Antibodies, Monoclonal","Granulocyte-Macrophage Colony-Stimulating Factor","Meta-Analysis as Topic","CTLA-4 Antigen","Humans"],"genes":["GM-CSF","Ipilimumab","granulocyte-macrophage colony-stimulating factor sargramostin","CTLA-4"],"publicationTypes":["Journal Article"],"abstract":"In a phase II trial, combining the granulocyte-macrophage colony-stimulating factor sargramostin and the CTLA-4 inhibitor ipilimumab prolonged survival and caused fewer serious side effects in patients with metastatic melanoma compared with ipilimumab alone. ","title":"GM-CSF/Ipilimumab combination extends melanoma survival.","pubmedId":"23847381"}